GAITHERSBURG, Md., Feb. 16, 2024/PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS ) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on February 16, 2024in Seattle, United States. The Company's sharehold...